Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib + Chidamide vs CHOP in PTCL
NCT06421948Phase 2Recruiting
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of linperlisib in peripheral T-cell lymphoma (PTCL) (4 arms). Primary endpoints: Recommended Phase 2 Dose at 3 months and Complete Response Rate at 3 years. Started May 2024; status: recruiting.
02
Drugs
linperlisib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06421948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421948.